The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials

TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) and its death receptors TRAIL-R1 and TRAIL-R2 selectively trigger the apoptotic cell death in tumor cells. For that reason, TRAIL has been extensively studied as a target of cancer therapy. In spite of the promising preclinical o...

Descripción completa

Detalles Bibliográficos
Autores principales: Snajdauf, Martin, Havlova, Klara, Vachtenheim, Jiri, Ozaniak, Andrej, Lischke, Robert, Bartunkova, Jirina, Smrz, Daniel, Strizova, Zuzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006409/
https://www.ncbi.nlm.nih.gov/pubmed/33791337
http://dx.doi.org/10.3389/fmolb.2021.628332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006409/
https://www.ncbi.nlm.nih.gov/pubmed/33791337
http://dx.doi.org/10.3389/fmolb.2021.628332

Ejemplares similares